Abstract
Background: Trimethoprim with sulfamethoxazole (TMP-SMX) is the drug of choice for the prophylaxis of AIDS-associated comorbidities.
Objective: To compare the efficacy and safety of two schemes of desensitization to TMP-SMX in HIV-positive patients.
Methods: A study was conducted from March 2018 to October 2019; it included HIV-positive patients who presented an adverse skin reaction to TMP-SMX; fifteen of them received desensitization scheme 1, which lasted ten days, and five patients received scheme 2, which lasted six hours.
Results: The average age of the patients who received scheme 1 was of 27.4 ± 5.7 years, while the average age of patients who received scheme 2 was of 33.6 ± 8 years. At baseline, the demographic, clinical, and immunological variables did not show significant differences between both groups (p> 0.05). In both groups, an efficacy of 100% was obtained and, in terms of safety, only three patients in group 1 presented rash and pruritus, however, the procedure was not suspended; the previous tolerated dose was resumed and, subsequently, the desensitization procedure continued.
Conclusions: Both schemes of desensitization to TMP-SMX showed efficacy and safety in HIV-positive patients, who frequently present adverse reactions to these medications.
References
VIH-SIDA [En línea]. Suiza: Organización Mundial de la Salud; 2020. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/hiv-aids
Carrillo-Maravilla E, Villegas-Jiménez A. El descubrimiento del VIH en los albores de la epidemia del sida. Rev Invest Clin. 2004;56(2):130-133. Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0034-83762004000200003#:~:text=No%20cabe%20duda%20que%20fue,Sinoussi%2C%20tambi%C3%A9n%20investigaban%20con%20retrovirus.
Vigilancia epidemiológica de casos de VIH/SIDA en México. Registro Nacional de Casos de SIDA. Actualización al 15 de noviembre de 2016. Secretaría de Salud/Dirección General de Epidemiología/Centro Nacional para la Prevención y Control del VIH/SIDA; 2016. Disponible en: http://www.censida.salud.gob.mx/descargas/epidemiologia/RN_DIA_MUNDIAL_2016a.pdf
Zuluaga J. Protocolo de estudio y manejo de infección por Pneumocystis jirovecii. Infectio. 2012;16(3):129-131. DOI: 10.1016/S0123-9392(12)70040-1
Warrington R. Drug allergy: causes and desensitization. Hum Vaccin Immunother. 2012;8(10):1513-1524. DOI: 10.4161/hv.21889
Solensky R. Drug desensitization. Immunol Allergy Clin North Am. 2004;24(3):425-443. DOI: 10.1016/j.iac.2004.03.008
Torgovnick J, Arsura E. Desensitization to sulfonamides in patients with HIV infection. Am J Med. 1990;88(5):548-549. DOI: 10.1016/0002-9343(90)90443-h
Absar N, Daneshvar H, Beall G. Desensitization to trimethoprim/sulfamethoxazole in HIV-infected patients. J Allergy Clin Immunol. 1994;98(6):1001-1005. DOI: 10.1016/s0091-6749(94)70048-6
Pyle R, Butterfield J, Yolcheck G, Podjasek JC, Rank MA, Li JTC. Successful outpatient graded administration of trimethoprim-sulfamethoxazole in patients without HIV and with a history of sulfonamide adverse drug reaction. J Allergy Clin Immunol Pract. 2014;2(1):52-58. DOI: 10.1016/j.jaip.2013.11.002
Hoosen K, Mosam A, Dlova N, Grayson W. An update on adverse cutaneous drug reactions in HIV/AIDS. Dermatopathology (Basel). 2019;6(2):111-125. DOI: 10.1159/000496389
Yoshizawa S, Yasuaka A, Kikuchi Y, Honda M, Gatanaga H, Tachikawa N, et al. A 5-day course of oral desensitization to trimethoprim/sulfamethoxazole (T/S) in patients with human immunodeficiency virus type-1 infection who were previously intolerant to T/S. Ann Allergy Asthma Immunol. 2000;85(3):241-244. DOI: 10.1016/S1081-1206(10)62474-X
Demoly P, Messaad D, Sahla H, Fabre J, Faucherre VF, André P. Six-hour trimethoprim-sulfamethoxazole–graded challenge in HIV-infected patients. J Allergy Clin Immunol. 1998;102(6):1033-1036. Disponible en: https://www.jacionline.org/article/S0091-6749(98)70343-4/fulltext
Carr A, Penny R, Cooper DA. Efficacy and safety of rechallenge with low-dose trimethoprim sulfamethoxazole in previously hypersensitive HIV-infected patients. AIDS. 1993;7(1):65-71. DOI: 10.1097/00002030-199301000-00010
Cribb A, Lee B, Trepanier L. Adverse reactions to sulphonamide and sul- phonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis. Adverse Drug React Toxicol Rev. 1996;15(1):9-50.
Belchi-Hernández J, Espinosa-Parra F. Management of adverse reactions to prophylactic trimethoprim-sulfamethoxazole in patients with human immunodeficiency virus infection. Ann Allergy Asthma Immunol. 1996;76(4):355-358. DOI: 10.1016/S1081-1206(10)60037-3
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2020 Revista Alergia México